Cargando…
Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone
BACKGROUND AND PURPOSE: Inhibition of cholesteryl ester transfer protein (CETP) with torcetrapib in humans increases plasma high density lipoprotein (HDL) cholesterol levels but is associated with increased blood pressure. In a phase 3 clinical study, evaluating the effects of torcetrapib in atheros...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2440088/ https://www.ncbi.nlm.nih.gov/pubmed/18536749 http://dx.doi.org/10.1038/bjp.2008.229 |
_version_ | 1782156531654983680 |
---|---|
author | Forrest, M J Bloomfield, D Briscoe, R J Brown, P N Cumiskey, A-M Ehrhart, J Hershey, J C Keller, W J Ma, X McPherson, H E Messina, E Peterson, L B Sharif-Rodriguez, W Siegl, P K S Sinclair, P J Sparrow, C P Stevenson, A S Sun, S-Y Tsai, C Vargas, H Walker, M West, S H White, V Woltmann, R F |
author_facet | Forrest, M J Bloomfield, D Briscoe, R J Brown, P N Cumiskey, A-M Ehrhart, J Hershey, J C Keller, W J Ma, X McPherson, H E Messina, E Peterson, L B Sharif-Rodriguez, W Siegl, P K S Sinclair, P J Sparrow, C P Stevenson, A S Sun, S-Y Tsai, C Vargas, H Walker, M West, S H White, V Woltmann, R F |
author_sort | Forrest, M J |
collection | PubMed |
description | BACKGROUND AND PURPOSE: Inhibition of cholesteryl ester transfer protein (CETP) with torcetrapib in humans increases plasma high density lipoprotein (HDL) cholesterol levels but is associated with increased blood pressure. In a phase 3 clinical study, evaluating the effects of torcetrapib in atherosclerosis, there was an excess of deaths and adverse cardiovascular events in patients taking torcetrapib. The studies reported herein sought to evaluate off-target effects of torcetrapib. EXPERIMENTAL APPROACH: Cardiovascular effects of the CETP inhibitors torcetrapib and anacetrapib were evaluated in animal models. KEY RESULTS: Torcetrapib evoked an acute increase in blood pressure in all species evaluated whereas no increase was observed with anacetrapib. The pressor effect of torcetrapib was not diminished in the presence of adrenoceptor, angiotensin II or endothelin receptor antagonists. Torcetrapib did not have a contractile effect on vascular smooth muscle suggesting its effects in vivo are via the release of a secondary mediator. Treatment with torcetrapib was associated with an increase in plasma levels of aldosterone and corticosterone and, in vitro, was shown to release aldosterone from adrenocortical cells. Increased adrenal steroid levels were not observed with anacetrapib. Inhibition of adrenal steroid synthesis did not inhibit the pressor response to torcetrapib whereas adrenalectomy prevented the ability of torcetrapib to increase blood pressure in rats. CONCLUSIONS AND IMPLICATIONS: Torcetrapib evoked an acute increase in blood pressure and an acute increase in plasma adrenal steroids. The acute pressor response to torcetrapib was not mediated by adrenal steroids but was dependent on intact adrenal glands. |
format | Text |
id | pubmed-2440088 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-24400882008-06-27 Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone Forrest, M J Bloomfield, D Briscoe, R J Brown, P N Cumiskey, A-M Ehrhart, J Hershey, J C Keller, W J Ma, X McPherson, H E Messina, E Peterson, L B Sharif-Rodriguez, W Siegl, P K S Sinclair, P J Sparrow, C P Stevenson, A S Sun, S-Y Tsai, C Vargas, H Walker, M West, S H White, V Woltmann, R F Br J Pharmacol Research Papers BACKGROUND AND PURPOSE: Inhibition of cholesteryl ester transfer protein (CETP) with torcetrapib in humans increases plasma high density lipoprotein (HDL) cholesterol levels but is associated with increased blood pressure. In a phase 3 clinical study, evaluating the effects of torcetrapib in atherosclerosis, there was an excess of deaths and adverse cardiovascular events in patients taking torcetrapib. The studies reported herein sought to evaluate off-target effects of torcetrapib. EXPERIMENTAL APPROACH: Cardiovascular effects of the CETP inhibitors torcetrapib and anacetrapib were evaluated in animal models. KEY RESULTS: Torcetrapib evoked an acute increase in blood pressure in all species evaluated whereas no increase was observed with anacetrapib. The pressor effect of torcetrapib was not diminished in the presence of adrenoceptor, angiotensin II or endothelin receptor antagonists. Torcetrapib did not have a contractile effect on vascular smooth muscle suggesting its effects in vivo are via the release of a secondary mediator. Treatment with torcetrapib was associated with an increase in plasma levels of aldosterone and corticosterone and, in vitro, was shown to release aldosterone from adrenocortical cells. Increased adrenal steroid levels were not observed with anacetrapib. Inhibition of adrenal steroid synthesis did not inhibit the pressor response to torcetrapib whereas adrenalectomy prevented the ability of torcetrapib to increase blood pressure in rats. CONCLUSIONS AND IMPLICATIONS: Torcetrapib evoked an acute increase in blood pressure and an acute increase in plasma adrenal steroids. The acute pressor response to torcetrapib was not mediated by adrenal steroids but was dependent on intact adrenal glands. Nature Publishing Group 2008-06-09 2008-08 /pmc/articles/PMC2440088/ /pubmed/18536749 http://dx.doi.org/10.1038/bjp.2008.229 Text en Copyright 2008, Nature Publishing Group http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/. |
spellingShingle | Research Papers Forrest, M J Bloomfield, D Briscoe, R J Brown, P N Cumiskey, A-M Ehrhart, J Hershey, J C Keller, W J Ma, X McPherson, H E Messina, E Peterson, L B Sharif-Rodriguez, W Siegl, P K S Sinclair, P J Sparrow, C P Stevenson, A S Sun, S-Y Tsai, C Vargas, H Walker, M West, S H White, V Woltmann, R F Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone |
title | Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone |
title_full | Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone |
title_fullStr | Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone |
title_full_unstemmed | Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone |
title_short | Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone |
title_sort | torcetrapib-induced blood pressure elevation is independent of cetp inhibition and is accompanied by increased circulating levels of aldosterone |
topic | Research Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2440088/ https://www.ncbi.nlm.nih.gov/pubmed/18536749 http://dx.doi.org/10.1038/bjp.2008.229 |
work_keys_str_mv | AT forrestmj torcetrapibinducedbloodpressureelevationisindependentofcetpinhibitionandisaccompaniedbyincreasedcirculatinglevelsofaldosterone AT bloomfieldd torcetrapibinducedbloodpressureelevationisindependentofcetpinhibitionandisaccompaniedbyincreasedcirculatinglevelsofaldosterone AT briscoerj torcetrapibinducedbloodpressureelevationisindependentofcetpinhibitionandisaccompaniedbyincreasedcirculatinglevelsofaldosterone AT brownpn torcetrapibinducedbloodpressureelevationisindependentofcetpinhibitionandisaccompaniedbyincreasedcirculatinglevelsofaldosterone AT cumiskeyam torcetrapibinducedbloodpressureelevationisindependentofcetpinhibitionandisaccompaniedbyincreasedcirculatinglevelsofaldosterone AT ehrhartj torcetrapibinducedbloodpressureelevationisindependentofcetpinhibitionandisaccompaniedbyincreasedcirculatinglevelsofaldosterone AT hersheyjc torcetrapibinducedbloodpressureelevationisindependentofcetpinhibitionandisaccompaniedbyincreasedcirculatinglevelsofaldosterone AT kellerwj torcetrapibinducedbloodpressureelevationisindependentofcetpinhibitionandisaccompaniedbyincreasedcirculatinglevelsofaldosterone AT max torcetrapibinducedbloodpressureelevationisindependentofcetpinhibitionandisaccompaniedbyincreasedcirculatinglevelsofaldosterone AT mcphersonhe torcetrapibinducedbloodpressureelevationisindependentofcetpinhibitionandisaccompaniedbyincreasedcirculatinglevelsofaldosterone AT messinae torcetrapibinducedbloodpressureelevationisindependentofcetpinhibitionandisaccompaniedbyincreasedcirculatinglevelsofaldosterone AT petersonlb torcetrapibinducedbloodpressureelevationisindependentofcetpinhibitionandisaccompaniedbyincreasedcirculatinglevelsofaldosterone AT sharifrodriguezw torcetrapibinducedbloodpressureelevationisindependentofcetpinhibitionandisaccompaniedbyincreasedcirculatinglevelsofaldosterone AT sieglpks torcetrapibinducedbloodpressureelevationisindependentofcetpinhibitionandisaccompaniedbyincreasedcirculatinglevelsofaldosterone AT sinclairpj torcetrapibinducedbloodpressureelevationisindependentofcetpinhibitionandisaccompaniedbyincreasedcirculatinglevelsofaldosterone AT sparrowcp torcetrapibinducedbloodpressureelevationisindependentofcetpinhibitionandisaccompaniedbyincreasedcirculatinglevelsofaldosterone AT stevensonas torcetrapibinducedbloodpressureelevationisindependentofcetpinhibitionandisaccompaniedbyincreasedcirculatinglevelsofaldosterone AT sunsy torcetrapibinducedbloodpressureelevationisindependentofcetpinhibitionandisaccompaniedbyincreasedcirculatinglevelsofaldosterone AT tsaic torcetrapibinducedbloodpressureelevationisindependentofcetpinhibitionandisaccompaniedbyincreasedcirculatinglevelsofaldosterone AT vargash torcetrapibinducedbloodpressureelevationisindependentofcetpinhibitionandisaccompaniedbyincreasedcirculatinglevelsofaldosterone AT walkerm torcetrapibinducedbloodpressureelevationisindependentofcetpinhibitionandisaccompaniedbyincreasedcirculatinglevelsofaldosterone AT westsh torcetrapibinducedbloodpressureelevationisindependentofcetpinhibitionandisaccompaniedbyincreasedcirculatinglevelsofaldosterone AT whitev torcetrapibinducedbloodpressureelevationisindependentofcetpinhibitionandisaccompaniedbyincreasedcirculatinglevelsofaldosterone AT woltmannrf torcetrapibinducedbloodpressureelevationisindependentofcetpinhibitionandisaccompaniedbyincreasedcirculatinglevelsofaldosterone |